Dual inhibitory mechanism of lapatinib and its application in breast cancer treatment

Lapatinib (Lapatinib) is an innovative dual inhibitor that can simultaneously inhibit the tyrosine kinases of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). Since its approval by the U.S. Food and Drug Administration (FDA) in 2007, it has quickly become an important drug for the treatment of advanced or metastatic breast cancer (MBC), especially for patients with MBC who overexpress HER2 and have received multiple treatments.

Pharmacokinetic studies of lapatinib have shown that the drug reaches peak concentration within3 to 4 hours after oral administration. It is worth noting that the way you take your medication and your diet will affect its area under the curve (AUC), so patients need to follow specific medication instructions. In addition, the drug is mainly metabolized by the cytochrome P450 3A4 isoenzyme, and one of its metabolites is active on EGFR but not on HER2, which highlights the precise targeting ability of lapatinib.

Clinical trial results fully confirmed the efficacy of lapatinib combined with capecitabine. In a phase III clinical trial, the combination therapy significantly improved response rates and prolonged time to disease progression in women with HER2-positive locally advanced or MBC compared with capecitabine alone. In addition, phase II trials also showed that lapatinib has anti-tumor activity in patients with MBC, inflammatory breast cancer and central nervous system metastasis, further expanding its clinical scope of application.

The recommended dose of lapatinib is 1250 mg orally daily, which needs to be taken continuously and in combination with capecitabine. However, combination therapy may be associated with some common toxic reactions, such as diarrhea, hand-foot syndrome, etc., but compared with other drugs, lapatinib has a lower incidence of cardiotoxicity.

Currently, the original version of lapatinib has been launched at home and abroad, and there are also generic versions available in India, Bangladesh and other places, providing patients with more treatment options. With the deepening of research and the expansion of clinical application, lapatinib is expected to play a more critical role in the treatment of breast cancer and other solid tumors.

In general, lapatinib brings new treatment hope to HER2-positive MBC patients through its unique dual inhibition mechanism Clinical trial results not only verify its significant efficacy, but also demonstrate its therapeutic advantages in specific patient groups.

xa0

Reference: https://pubmed.ncbi.nlm.nih.gov/18803986/